XenoSTART is a global nonclinical oncology contract research organization focused on the development and utilization of patient-derived xenograft models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models. 

​

​Our XPDX models are clinically annotated and include patient treatment history and outcome and are characterized through genomic profiling, histologic analysis, and in vivo drug sensitivity to relevant standards of care. These models may be utilized in the following manner: 

​

• In vivo PK/PD and efficacy studies

• In vivo efficacy panel screens (indication or target focused)

• In licensing of models for internal studies

• Custom model development 

• Orthotopic and radiotherapy studies 

• Ex vivo and organoid studies